Panel: Megamergers, Mega-Rounds and the Next Deal Cycle

Session details:

As pharma stares down one of its biggest patent cliffs in decades, the pressure to replenish pipelines is driving larger bets across the industry. Alongside renewed speculation about pharma megamergers, biotech has also seen a rise in mega-rounds as investors concentrate capital behind companies with the strongest science and clearest paths to value. This session will look at what is driving the return of big-ticket dealmaking, how companies are adjusting their M&A strategies ahead of major loss-of-exclusivity hits and whether the industry is entering a new era of larger, more concentrated bets.